HEAD-TO-HEAD

GLP-1 / GLUCAGON DUAL AGONIST VS GLP-1 / GIP DUAL AGONIST

the GLP-1/glucagon dual agonist and the GLP-1/GIP dual agonist are both next-generation dual incretin research compounds, with different receptor pairings. the GLP-1/glucagon dual agonist is a GLP-1 + glucagon dual agonist (the originator pharma sponsor BI 456906). the GLP-1/GIP dual agonist is a GLP-1 + GIP dual agonist (the originator pharma sponsor the FDA-approved class member / the FDA-approved class member). The glucagon-receptor arm in the GLP-1/glucagon dual agonist adds a thermogenic / energy-expenditure component absent from the GLP-1/GIP dual agonist.

A · No. 019

GLP-1 / GLUCAGON DUAL AGONIST

Investigational incretin combination

B · No. 002

GLP-1 / GIP DUAL AGONIST

Combined incretin receptor activation

SIDE BY SIDE

FIELD

A · GLP-1 / GLUCAGON DUAL AGONIST

B · GLP-1 / GIP DUAL AGONIST

Class

GLP-1 + glucagon dual agonist

GLP-1 + GIP dual agonist

Development code

BI 456906

LY3298176

Half-life

~7 days (once-weekly)

~5 days (once-weekly)

Receptors engaged

GLP-1R + glucagon receptor (GCGR)

GLP-1R + GIPR

Best published Phase 2/3 outcome

-14.9% placebo-subtracted BW at 4.8 mg/wk, 46 wk (Le Roux 2024 Lancet D&E)

-22.5% BW at 72 wk, 15 mg (SURMOUNT-1)

FDA status

Investigational · Phase 3 SYNCHRONIZE-1/2 enrolling

FDA-approved (the FDA-approved class member 2022, the FDA-approved class member 2023)

NASH/MASH activity

Phase 2 reported improved liver fat + histology (Sanyal NEJM 2024)

Not the lead Phase 3 indication

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ Validated human-prescription pathwayB · GLP-1 / GIP DUAL AGONIST

the GLP-1/GIP dual agonist has FDA approval, the SURPASS / SURMOUNT Phase 3 program, and millions of post-marketing prescriptions. the GLP-1/glucagon dual agonist is investigational.

▶ Thermogenic / energy-expenditure axisA · GLP-1 / GLUCAGON DUAL AGONIST

Glucagon-receptor agonism drives hepatic lipolysis and energy expenditure on top of appetite suppression. GIP agonism (the GLP-1/GIP dual agonist) acts more through adipocyte lipid handling and insulin secretion.

▶ NASH/MASH researchA · GLP-1 / GLUCAGON DUAL AGONIST

the GLP-1/glucagon dual agonist Phase 2 (Sanyal 2024 NEJM) reported improved liver fat fraction and histology endpoints, supporting a dedicated NASH Phase 3 program.

▶ T2D glycemic control track recordB · GLP-1 / GIP DUAL AGONIST

the GLP-1/GIP dual agonist has the SURPASS Phase 3 program including head-to-head data versus the long-acting GLP-1 agonist (SURPASS-2, NEJM 2021).

STACKING NOTE

Combining multiple incretin agonists is not supported by published research. They engage overlapping GLP-1 pathways and combined use is unstudied. Buyers researching the dual-incretin category typically order both as parallel reference compounds, not for simultaneous use.

SOURCED FROM GIGACOMPOUNDS

Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE AT GIGACOMPOUNDS ▶